The purpose of this study is to evaluate the safety and effectiveness of the investigational drug MEDI4736 in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) that has continued to grow despite at least two prior regimens of therapy, at least one of which included a platinum-containing drug.
MEDI4736 is an antibody designed to boost the body’s immune system by targeting a protein on tumor cells called PD-L1. PD-L1 normally maintains the balance of the immune system. In cancer, PD-L1 helps tumors evade detection and elimination by the immune system. MEDI4736 may increase the immune system’s ability to identify and destroy cancer cells. It is given intravenously (by vein).